Clinical Trial

The Efficacy and Safety of PEGylated GH for the Treatment of Short Stature in Chinese Children-GLOBE Reg

Recruiting
View on ClinicalTrials.gov →
Summary
In order to further observe the long-term safety and effectiveness of real-world polyethylene glycol-recombinant human growth hormone(PEG-rhGH) treatment of GHD, idiopathic short stature, and SGA in children, explore and analyze the factors affecting the efficacy of PEG-rhGH and the height prediction model after treatment, etc., collect and analyze more scientifically and rationally, and understand the situation of real-world PEG-GH treatment. A database registration study was developed.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-09-12.
Trial Details
NCT Number NCT06037473
Lead Sponsor Beijing Children's Hospital
Collaborators: University of Glasgow
Conditions Growth Hormone Treatment, Growth Disorders
Enrollment 2,600 participants
Start Date 2023-08-01
Primary Completion 2029-01-01 (estimated)
Study Completion 2029-08-01 (estimated)
Updated on ClinicalTrials.gov 2025-09-04